Indeed, an indirect comparison meta-analysis found that the combination of chemotherapy plus anti-PD-1 agent provides better OS benefit than chemotherapy plus anti-PD-L1 agent in patients with NSCLC [20]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.